Actinogen Medical Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven G. Gourlay
- Full Time Employees
- 6
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 109 Pitt Street Sydney NSW Australia 2000
- IPO Date
- Aug 22, 2007
- Website
- actinogen.com.au
- Similar Companies
- Business
- Actinogen Medical Limited is an Australian biotechnology firm dedicated to developing treatments for a range of neurological and neuropsychiatric conditions linked to imbalanced brain cortisol levels. The company is advancing Xanamem (emestedastat), an oral small molecule that selectively inhibits the 11β-HSD1 enzyme to modulate cortisol within the brain. Xanamem is currently undergoing a pivotal Phase 2b/3 clinical trial for Alzheimer's disease in Australia and the United States, targeting mild to moderate forms of the condition. Further, Xanamem has shown positive Phase 2a results for cognitive impairment in Major Depressive Disorder and is also being explored for its potential in Fragile X Syndrome. Established in 1999, the company adopted its current name in November 2015 and operates from Sydney, Australia.
Company News
Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings
Actinogen Medical closes September quarter with XanaMIA readout in sight
Actinogen's Xanamem trial hits key milestone ahead of results - ICYMI
Actinogen Medical completes final XanaMIA patient visit; November Alzheimer's trial results on track
Dow slips, Nasdaq edges lower as August ends in green
Nvidia's $12.9bn Hugging Face swoop is really about filling the cloud capacity it has underwritten
UBS says bond market relief from falling yields will not offset deeper structural pressures
Riot Platforms $9.1B AI deal fuels speculation around Anthropic IPO
Traders see little chance of Hormuz shipping recovery by end of August
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results
The Small Cap Watch: Healthcare, critical minerals and gold explorers advance projects
Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI
Novo Resources expands Wyloo silver targets - ICYMI
Horizon Gold details A$1.31B Gum Creek NPV - ICYMI
Resolution Minerals secures second FAST-41 status - ICYMI
Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial